Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Hutchison MediPharma to Receive $10 Million Milestone from Lilly

publication date: Oct 27, 2015
Hutchison MediPharma will receive a $10 million milestone in Q4 from its partner Eli Lilly for achieving a positive proof-of-concept in its Phase II clinical trial of fruquintinib, a cancer drug. MediPharma discovered fruquintinib and out-licensed it to Lilly in 2013. The milestone was a payment for POC in patients with advanced non-squamous non-small cell lung cancer in China. Earlier this year, MediPharma received another $10 million milestone for completing fruquintinib POC as a treatment for metastatic colorectal cancer. More details....

Stock Symbols: (AIM: HCM) (NYSE: LLY)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital